Beyond the peptide category
SLU-PP-332
An experimental small molecule studied for effects on estrogen-related receptors and energy metabolism. SLU-PP-332 is not a peptide.
Non-peptide compounds · Educational information only · No medical advice
← Peptide library · Start Here
Non-peptide research compoundAlso discussed as: SLU PP 332, SLUPP332; sometimes called an exercise mimetic
What it is and how it works
SLU-PP-332 activates estrogen-related receptors ERR alpha, beta, and gamma, with the strongest activity against ERR alpha in the cited experiments. These nuclear receptors regulate gene expression involved in cellular energy use. The name refers to a receptor family; it does not mean the compound is estrogen. Researchers observed changes in muscle-cell respiration and exercise-related gene expression. This is a proposed research mechanism, not proof of a clinical benefit.
Source for this context →A closer look at the cited evidence
Animal + laboratory study
This label describes the selected source below. It is not a complete ranking of the literature, a safety score, or an approval status.
- Study or assessment
- Billon et al., 2023 — synthetic ERR agonist and exercise capacity
- Design
- Preclinical laboratory and mouse experiments, including comparisons with vehicle controls.
- Who or what was studied
- Cell-based assays and mice; not people taking SLU-PP-332.
- What was observed
- Researchers reported increased muscle-cell mitochondrial activity, changes in oxidative muscle fibers, and improved running endurance in mice. ERR alpha signaling was important to the response.
- Limits of interpretation
- These findings do not establish human performance improvement, safe human use, or a replacement for exercise. Some authors disclosed ownership interests in a company developing ERR therapeutics.
Regulatory context
The cited evidence concerns a preclinical research compound and does not establish an approved human treatment indication. An online product listing or a research-use-only label is not evidence of FDA approval. This library does not recommend its use or provide prescribing instructions.
Safety considerations
The selected studies do not establish a human adverse-effect profile, interactions, or long-term safety. Limited toxicity observations in laboratory animals cannot show that a compound is safe for people. Commercial product identity, purity, and formulation are separate uncertainties. Absence of reported human harm in these papers is not evidence of safety.
What remains uncertain
A separate mouse study reported increased energy expenditure and fat oxidation, with reduced fat accumulation in obesity models. That result does not demonstrate weight loss in people. Human effectiveness, absorption, interactions, and long-term outcomes remain unanswered by these sources. Exercise mimetic describes selected experimental responses; it does not mean exercise in a pill or reproduce all benefits of physical activity. This profile provides no dosing, injection, reconstitution, or stacking guidance.